"What" Series

What is site-directed mutagenesis?

22 December 2023
2 min read

Site-directed mutagenesis is a molecular biology technique that is used to make specific and intentional changes to the DNA sequence of a gene and any protein that it may encode. It is also known as site-specific mutagenesis or oligonucleotide-directed mutagenesis. This method involves usage of specific primers carrying the mutation that needs to be introduced into the DNA sequence. These primers are designed to hybridize to the template DNA at the site of the desired mutation. Polymerases used in this method can synthesize new strands of DNA containing the desired mutation from this starting point.

The method has been used to study the structure and function of different proteins and enzymes, by introducing specific mutations and observing the resulting changes in protein function. This has provided valuable insights into protein structure and function, and has helped in understanding the biological processes at the molecular and atomic level.

This method is also used in the production of proteins with improved or novel functions, and in the production of genetically modified organisms.

In regards to DNA sequencing, site-directed mutagenesis can be used to create specific DNA sequences with known mutations. These mutated sequences can then be compared to the normal, non-mutated sequence to help identify the specific effects of the mutation. Furthermore, site-directed mutagenesis can be used to create and study specific mutations that are suspected to be associated with certain diseases or conditions in humans. This can both increase our understanding of the disease and help to develop potential treatments.

Where traditional DNA sequencing provides the order of base pairs in a DNA sequence, site-directed mutagenesis can manipulate these sequences to study the functions of specific genes, helping scientists understand how changes in DNA lead to different protein creations and gene expressions. It's a powerful tool in genetic engineering and biotechnology.

1ST Biotherapeutics, Inc. launches phase I/II trial of FB849 for progressive solid cancers
Latest Hotspot
3 min read
1ST Biotherapeutics, Inc. launches phase I/II trial of FB849 for progressive solid cancers
22 December 2023
1ST Biotherapeutics, Inc. breaks new ground as it initiates the first human trial stage I/II by administering FB849, to individuals with progressive solid cancers
Read →
Exploring TT-00434's R&D successes and its clinical results at the 2023 ESMO_ASIA
ESMO 2023
4 min read
Exploring TT-00434's R&D successes and its clinical results at the 2023 ESMO_ASIA
22 December 2023
TT-00434 is an irreversible, highly selective inhibitor of FGFR1, 2, and 3 with potent preclinical activity against tumors harboring FGFR aberrations.
Read →
C4 Therapeutics Reports Encouraging Results from Initial Study of CFT7455 in Recurrent/Resistant Multiple Myeloma Cases
Latest Hotspot
4 min read
C4 Therapeutics Reports Encouraging Results from Initial Study of CFT7455 in Recurrent/Resistant Multiple Myeloma Cases
22 December 2023
C4 Therapeutics, Inc., a company developing targeted protein degradation drugs, has announced early results from its Phase 1/2 trial's initial dose-escalation stage. The trial evaluates CFT7455, a unique MonoDAC™ agent targeting IKZF1/3 proteins, for treating multiple myeloma and non-Hodgkin lymphomas.
Read →
What are oligonucleotide drugs?
"What" Series
2 min read
What are oligonucleotide drugs?
22 December 2023
Oligonucleotide drugs are a class of medications that are composed of short, synthetic pieces of DNA or RNA known as oligonucleotides.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.